Françoise Meunier, Vice President of the Royal Academy of Medicine of Belgium, and Founder of the European Initiative on Ending Discrimination Against Cancer Survivors, shared a post on LinkedIn:
“A recent Lancet Regional Health Europe study of nearly 72,000 young cancer survivors in the Netherlands provides compelling evidence for revising current Right to Be Forgotten (RTBF) measures:
For most adolescent and young adult (AYA) survivors, the risk of excess mortality is minimal (survival >95%) within just 4 years after diagnosis.
Some cancers, like testicular, thyroid, melanoma, and neuroendocrine tumors, showed minimal excess mortality from the moment of diagnosis.
These findings challenge the current 7–10 year disclosure periods required by RTBF laws in many EU countries.
These findings are crucial for re-evaluating the ‘Right to be Forgotten’ law in the Netherlands (which still requires disclosure up to 10 years), but also in other EU Member States. This study suggests that AYAs, who often face financial discrimination due to their cancer history, may benefit from shorter disclosure periods, ensuring their fair treatment in insurance and other financial matters.”
Quoting Cancer Patients Europe’s post:
“CPE Highlights New Lancet Study on the ‘Right to Be Forgotten’ for Young Cancer Survivors
A new study in The Lancet Regional Health – Europe shows that most young cancer survivors reach near-normal survival far earlier than the current 10-year disclosure period required for insurance, loans, and mortgages in many EU countries.
CPE continues to advocate for fairer ‘right to be forgotten’ policies that reflect the latest evidence and ensure young survivors can access opportunities without unnecessary barriers.
Title: 5-Year conditional relative survival of adolescents and young adults with solid malignancies in the Netherlands: a population-based cohort study
Authors: Noelle J. M. C. Vrancken Peeters, Daniël J. van der Meer, Bo Wardenier, Marion L’hôte, Eveliene Manten-Horst, Henrike E. Karim-Kos, Winette T. A. van der Graaf, Olga Husson
Read the Full Article on The Lancet
More posts featuring Françoise Meunier.